[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"influenza-type-b\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:influenza-type-b":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100587418",false,"NCT06928129","Clinical Feasibility of the BinaxNOW™ COVID-19\u002FFlu A&B Combo in the Southern Hemisphere","Inclusion Criteria:\n\n* Participant is at least two (2) years of age, AND Participant is suspected of acute viral respiratory infection by a healthcare professional, AND\n* Participant is within five (5) days of symptom onset, AND\n\nParticipant is experiencing two or more of the following symptoms:\n\nFever of \\>100.0°F\u002F 37.8°C or chills, Cough, Fatigue, New loss of taste or smell, Congestion or runny nose, Shortness of breath or difficulty breathing, Sore throat, Muscle or body aches, Headache\n\n-The Participant and\u002For legally authorized representative is willing to undergo the informed consent\u002FAssent process prior to study participation. A minor will need the documented consent of their parent or legal guardian unless the site has an HREC waiver for parental consent for minors.\n\nExclusion Criteria:\n\n* Participant is currently enrolled in a study to evaluate an investigational drug or experimental treatment\n* Participants with an active nosebleed\n* Participant has undergone a nasal wash or nasal aspirate procedure on day of enrolment\n* Participant has tested positive for COVID-19 within the last 45 days\n* Participant has received a nasal vaccine (i.e. FluMist®) within the past 30 days.\n* Participant has received antiviral medications for Influenza (Amantadine, Rimantadine, Ribavirin, Oseltamivir, Zanamivir) in the previous 45 days.\n* Participant has received medication or treatment for COVID-19 infection in the last 45 days (including antivirals (such as Paxlovid), convalescent plasma therapy, monoclonal antibody treatment (mAb), Remdesivir, long-acting antibody (LAAB) treatment (Evusheld)\n* Participant is unable to meet all inclusion criteria as listed above","ALL","2 Years",{"count":17,"type":18},700,"ESTIMATED","INTERVENTIONAL",[21],"NA","The study is designed as a clinical feasibility, to investigate the positive and negative percent agreement (PPA and NPA) of the BinaxNOW™ COVID-19\u002FFlu A\\&B Combo against a highly sensitive PCR method(s) in symptomatic patients suspected of SARS-CoV-2 or influenza infection when nasal swabs are self-collected by the patient\u002Flay user.",[24,25,26],"Influenza Type A","Influenza Type B","COVID-19","NOT_YET_RECRUITING","2025-04-10",{"date":30,"type":31},"2025-04-15","ACTUAL",{"date":33,"type":18},"2025-06-30",{"date":35,"type":18},"2025-11-01",{"name":37,"class":38},"Abbott Rapid Dx","INDUSTRY",""]